Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedJan 16, 2026
DataAggregated Company Financials
Companies545
  • 7D-0.8%
  • 3M11.1%
  • 1Y26.8%
  • YTD0.9%

Last week, the Biotech industry hasn't moved much but Revolution Medicines is up 15% in that time. As for the the longer term, the industry is up 27% over the past 12 months. Looking forward, earnings are forecast to grow by 23% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 16 Jan 2026US$1.2tUS$163.5b-US$15,150,534,323.5420.1x-81.7x7.6x
Sun, 14 Dec 2025US$1.2tUS$163.7b-US$15,628,369,300.4319x-78x7.4x
Tue, 11 Nov 2025US$1.1tUS$163.6b-US$15,778,894,049.8917.1x-71.9x6.9x
Thu, 09 Oct 2025US$1.1tUS$163.4b-US$18,204,173,729.7516.7x-62.5x7x
Sat, 06 Sep 2025US$1.1tUS$163.6b-US$18,346,651,759.6015.7x-58.4x6.5x
Mon, 04 Aug 2025US$1.0tUS$158.4b-US$20,947,422,497.0215.8x-48.4x6.4x
Wed, 02 Jul 2025US$927.2bUS$156.0b-US$23,839,320,142.0917.5x-38.9x5.9x
Fri, 30 May 2025US$914.8bUS$155.9b-US$23,981,521,247.8015.7x-38.1x5.9x
Sun, 27 Apr 2025US$783.3bUS$119.2b-US$31,074,126,492.8219.8x-25.2x6.6x
Tue, 25 Mar 2025US$827.0bUS$118.6b-US$36,869,226,191.9320.7x-22.4x7x
Thu, 20 Feb 2025US$842.4bUS$116.6b-US$36,830,915,932.5217.4x-22.9x7.2x
Sat, 18 Jan 2025US$943.3bUS$149.4b-US$26,286,132,923.6717.3x-35.9x6.3x
Mon, 16 Dec 2024US$991.8bUS$150.0b-US$26,493,336,471.9416.6x-37.4x6.6x
Wed, 13 Nov 2024US$1.1tUS$149.6b-US$27,274,668,753.1816.1x-40.4x7.4x
Fri, 11 Oct 2024US$885.7bUS$113.1b-US$35,992,841,232.3420.3x-24.6x7.8x
Sun, 08 Sep 2024US$873.8bUS$113.1b-US$35,668,533,175.3222.2x-24.5x7.7x
Tue, 06 Aug 2024US$1.2tUS$165.8b-US$32,345,907,600.2024.9x-37x7.2x
Thu, 04 Jul 2024US$1.1tUS$164.5b-US$27,946,912,225.8427.9x-40.1x6.8x
Sat, 01 Jun 2024US$1.1tUS$164.6b-US$26,677,227,566.3227.4x-41.6x6.7x
Mon, 29 Apr 2024US$1.1tUS$164.6b-US$27,372,800,636.0922.6x-39.1x6.5x
Wed, 27 Mar 2024US$1.2tUS$164.4b-US$23,792,606,116.0221.2x-48.8x7.1x
Fri, 23 Feb 2024US$1.2tUS$169.0b-US$20,212,652,991.5813.2x-57x6.8x
Sun, 21 Jan 2024US$1.4tUS$204.8b-US$22,506,538,466.0018.5x-63.3x7x
Tue, 19 Dec 2023US$1.4tUS$204.7b-US$22,117,247,361.0019.2x-61x6.6x
Thu, 16 Nov 2023US$1.2tUS$204.7b-US$22,143,559,902.0018.4x-55.1x6x
Sat, 14 Oct 2023US$1.3tUS$207.3b-US$13,141,713,262.0016.6x-96.4x6.1x
Mon, 11 Sep 2023US$1.3tUS$207.5b-US$12,633,744,533.0017.4x-101x6.1x
Wed, 09 Aug 2023US$1.3tUS$206.4b-US$12,500,248,802.0016.4x-101x6.1x
Fri, 07 Jul 2023US$1.1tUS$186.2b-US$16,056,868,924.0013.2x-69.5x6x
Sun, 04 Jun 2023US$1.1tUS$185.9b-US$16,014,255,509.0011.4x-71.1x6.1x
Tue, 02 May 2023US$1.2tUS$197.0b-US$6,677,740,450.0014x-175.7x6x
Thu, 30 Mar 2023US$1.1tUS$198.3b-US$4,280,712,821.0013.8x-266.8x5.8x
Sat, 25 Feb 2023US$1.1tUS$200.5b-US$3,797,679,065.0014.2x-295.4x5.6x
Mon, 23 Jan 2023US$1.2tUS$203.8bUS$1.8b14.4x655.9x5.7x
Price to Earnings Ratio

655.9x


Total Market Cap: US$1.2tTotal Earnings: US$1.8bTotal Revenue: US$203.8bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -30.7x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.6x is lower than the industry's current PS ratio of 7.6x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 7.1% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.31%
Healthcare-0.84%
Biotech-0.78%
Biotech-0.78%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
RVMD Revolution MedicinesUS$123.2714.8%
+US$3.1b		208.9%PB14.9x
MRNA ModernaUS$39.3616.2%
+US$2.1b		16.6%PS6.9x
ONC BeOne MedicinesUS$338.295.6%
+US$2.0b		64.7%PE546.1x
BNTX BioNTechUS$106.077.3%
+US$1.8b		-5.9%PS7.3x
IBRX ImmunityBioUS$3.9576.3%
+US$1.7b		29.9%PS47.1x

Latest News

IBRX
US$3.95
ImmunityBio
7D
76.3%
1Y
29.9%
ALNY
US$359.26
Alnylam Pharmaceuticals
7D
-9.8%
1Y
45.9%
MDGL
US$495.88
Madrigal Pharmaceuticals
7D
-10.8%
1Y
81.8%
MRNA
US$39.36
Moderna
7D
16.2%
1Y
16.6%
ROIV
US$23.30
Roivant Sciences
7D
7.0%
1Y
114.0%
RVMD
US$123.27
Revolution Medicines
7D
14.8%
1Y
208.9%
KRYS
US$282.01
Krystal Biotech
7D
13.3%
1Y
94.7%
BIIB
US$168.57
Biogen
7D
-9.4%
1Y
19.4%
BNTX
US$106.07
BioNTech
7D
7.3%
1Y
-5.9%
ERAS
US$9.56
Erasca
7D
64.5%
1Y
414.0%
SMMT
US$17.27
Summit Therapeutics
7D
-8.3%
1Y
-5.1%
INSM
US$159.27
Insmed
7D
-6.5%
1Y
118.9%
REGN
US$741.92
Regeneron Pharmaceuticals
7D
-7.4%
1Y
7.0%

REGN: Core Franchises And Pipeline Will Support Balanced Upside And Concentration Risks

Analysts have raised their fair value estimate for Regeneron Pharmaceuticals from about $781 to roughly $821. This reflects updated price targets that reference a slightly lower discount rate, modestly adjusted revenue growth assumptions, a small uptick in expected profit margins, and a higher future P/E multiple supported by recent bullish research calls from several major firms.
VRTX
US$438.92
Vertex Pharmaceuticals
7D
-6.5%
1Y
5.3%

VRTX: CF Durability And Kidney Pipeline Data Will Define Next Phase

Analysts have lifted their Vertex Pharmaceuticals fair value estimate by about US$11 to US$496.16, reflecting updated assumptions on revenue growth, margins and future P/E, as recent research highlights confidence in the durability of its cystic fibrosis franchise and potential upside from its broader pipeline. Analyst Commentary Recent Street research around Vertex Pharmaceuticals points to a generally constructive view, with most commentary focusing on the durability of the cystic fibrosis franchise, the breadth of the pipeline and how these factors feed into valuation targets and rating changes.
ABBV
US$216.75
AbbVie
7D
-3.3%
1Y
24.8%

ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution

Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.
ONC
US$338.29
BeOne Medicines
7D
5.6%
1Y
64.7%

ONC: Fair View Balances Blood Cancer Progress With Gastroesophageal Cancer Opportunity

The analyst price target for BeOne Medicines has moved higher to reflect a fair value estimate of $292.03, with analysts pointing to stronger modeled revenue growth and profit margins, supported by recent Street research around Brukinsa performance, Ziihera phase III progress in HER2-positive GEA with Tevimbra, and continued confidence in the CLL and solid tumor pipeline. Analyst Commentary Recent Street research on BeOne Medicines has generally pointed to constructive views on the company’s core franchises, with several price targets adjusted higher alongside updates on Brukinsa, sonrotoclax, and the broader CLL and solid tumor pipeline.